The growth of disseminated tumor cells into metastatic lesions depends on the establishment of a favorable microenvironment in the stroma of the target organs. Here we show that mice treated with anakinra, an antagonist of the interleukin (IL)-1β receptor (IL-1R), or harboring a targeted deletion of IL-1R are significantly less prone to develop bone tumors when inoculated in the arterial circulation with human prostate cancer (PCa) cells expressing IL-1β. Interestingly, human mesenchymal stem cells exposed in vitro to medium conditioned by IL-1β-expressing cancer cells responded by upregulating S100A4, a marker of cancer-associated fibroblasts (CAFs), and this effect was blocked by anakinra. Analogously, the stroma adjacent to skeletal metastases generated in mice by IL-1β-expressing cancer cells showed a dramatic increase in S100A4, COX-2 and the alteration of 30 tumor-related genes as measured by Nanostring analysis. These effects were not observed in the stroma associated with the rare and much smaller metastases generated by the same cells in IL-1R knockout animals, confirming that tumor-secreted IL-1β generates skeletal CAFs and conditions the surrounding bone microenvironment. In skeletal lesions from patients with metastatic PCa, histological and molecular analyses revealed that IL-1β is highly expressed in cancer cells in which the androgen receptor (AR) is not detected (AR − ), whereas this cytokine is uniformly absent in the AR-positive (AR+) metastatic cells. The stroma conditioned by IL-1β-expressing cancer cells served as a supportive niche also for coexisting IL-1β-lacking cancer cells, which are otherwise unable to generate tumors after independently seeding the skeleton of mice. This niche is established very early following tumor seeding and hints to a role of IL-1β in promoting early colonization of PCa at the skeletal level.
INTRODUCTION
During the initial settlement that follows extravasation into target organs, cancer cells may benefit from existing supportive niches or must condition the surrounding stroma in their favor. The second event involves the recruitment of bystander cells in the normal parenchyma and the establishment of a habitat prone to tumor growth. It is widely recognized that these tumor-initiating abilities are not shared by all cancer cells but rather are a prerogative of a restricted fraction of malignant phenotypes. On a quest for signaling molecules capable of conditioning the bone microenvironment in support of metastatic growth, we focus on interleukin (IL)-1β, a cytokine that has been associated with tumor-promoting effects [1] [2] [3] but with only circumstantial implication in metastasis. 4 In a previous study, we used DNA microarray-based screening and identified IL-1β as an overexpressed gene conferring metastatic behavior to the human PC3-ML cells tested in animal models. 5 Building on this initial evidence, in this study we used the same animal model to show a clear impairment of skeletal tumor growth upon systemic administration of an IL-1β receptor (IL-1R) inhibitor. Furthermore, the use of transgenic mice knockout for IL-1R provided additional support to the idea that tumor-derived IL-1β is necessary for conditioning the bone stroma into a metastasis-receptive niche. In addition, in vitro studies and the harvesting of tumor-associated bone stroma in mice suggested a local development of cancer-associated fibroblasts (CAFs) from mesenchymal stem cells (MSCs) and alteration of 30 tumorassociated genes-including COX-2-both resulting from signaling through IL-1R. To correlate this preclinical evidence with human pathology, we tested skeletal metastases from 10 different prostate cancer (PCa) patients for IL-1β expression and found a considerable fraction of cancer cells with undetectable AR also lacking IL-1β. Notably, the inverse relationship between androgen receptor (AR) and IL-1β expression we observed in human metastatic PCa cells corresponds, in animal models, to a bone metastatic behavior restricted exclusively to the AR − /IL-1β-expressing phenotype of PC3-ML cells. Finally, the metastatic niche generated by PC3-ML also supports the growth of the PCa malignant phenotypes that lack IL-1β and consistently fail to survive after disseminating to the skeleton. Based on these findings, we propose that PCa cells secreting IL-1β are instrumental in priming the bone metastatic niche for initial colonization.
RESULTS

Antagonism of IL-1β signaling impairs metastasis
We grafted human cancer cells directly into the arterial circulation of SCID mice via the left cardiac ventricle, thus generating circulating tumor cells that disseminate systemically in an unbiased manner and closely reproduce the spreading of solid tumors in human patients. 6 Stably fluorescent PC3-ML cells, a subline of the parental PC3 7 that lacks AR, highly expresses IL-1β 5 and shows metastatic tropism for the skeleton, 8 were inoculated in mice pretreated for 1 day with either vehicle or the IL-1R antagonist anakinra 9 ; these treatments continued daily for 2 weeks until killing. Animals treated with anakinra showed a significant and dose-dependent reduction in tumor burden (Figures 1a and b) as compared with controls. Notably, the impairment in tumor growth observed in animals treated with 40 mg/kg of anakinra equaled the results we obtained in a previous study by silencing IL-1β expression via RNA interference. 5 IL-1β recruits the bone stroma to support tumor growth in the skeleton Tumor-derived IL-1β could act in a paracrine manner on the surrounding bone stroma, which might then reciprocate by providing crucial trophic support for tumor growth. To specifically address this issue, we generated IL-1R knockout SCID mice and inoculated them and their IL-1R wild-type (WT) littermates with PC3-ML cells, killing after 2 weeks. The absence of IL-1R in the bone stroma harboring the disseminated cancer cells in knockout animals completely prevented tumor growth in 50% of these mice ( Figure 1c ) and dramatically reduced the size of the skeletal tumors detected in the remaining animals (Figures 1d and e) .
Tumor-derived IL-1β converts bone human MSCs (hMSCs) into CAFs in vitro and induces the expression of CAFs markers and bone stromal alterations in vivo Having thus identified the stroma as a key driver of IL-1β-mediated metastasis, we sought to further explore its activity during skeletal metastatic progression. We exposed hMSCs in vitro for 1 week to IL-1β peptide (25 pg/ml) or conditioned media (CM) from PC3-ML cells and then examined for morphological and biochemical markers indicating their conversion to CAFs. 10 CAFs have a well-established role in primary tumors 11, 12 and are widely thought to act similarly at secondary sites. We found that hMSCs responded to IL-1β by formation of elongated actin stress fibers, suggestive of a transition into CAFs;
13 a similar change in morphology was generated by CM from PC3-ML cells, which are known to secrete IL-1β. 5 In either case, the effect observed was Figure 1 . Targeting IL-1β in animal models and evidence that tumor-derived IL-1β recruits the bone stroma in the metastatic niche (a and b) Animals were treated daily with the IL-1R antagonist anakinra or vehicle starting 1 day prior to cancer cell inoculation and continuing until killing at 2 weeks. Total tumor area measured in both knee joints for each mouse showed a dose-dependent reduction in response to anakinra treatment; at the higher dose, the decrease in tumor burden was comparable to that observed in our previous studies using shRNA-mediated IL-1β knockdown in PC3-ML cells. 5 Five animals each were used for vehicle and 40 mg/Kg anakinra, eight animals for 20 mg/Kg anakinra. (c) SCID mice WT or null (KO) for the IL-1R inoculated with PC3-ML cells and killed after 2 weeks. Upon killing, 50% of the knockout animals were free of metastatic lesions in the knee joint, while all WT animals harbored tumors. (d and e) Among the IL-1R KO mice that did form tumors, total tumor area was significantly reduced relative to their WT counterparts. Seven animals were used for IL-1R WT and six animals for IL-1R KO. (Dot-plot data: *P = 0.03; **P = 0.008 by one-way analysis of variance-total tumor area data are expressed as mean ± s.e. *P o0.05 by Student's t-test).
abrogated by inclusion of anakinra in the culture medium ( Figure 2a ). Consistent with this finding, the expression of the CAF-marker S100A4 (also known as FSP1) increased in hMSCs exposed to either IL-1β peptide or CM from PC3-ML cells, an effect which again was blocked by anakinra ( Figure 2b ). In light of these in vitro findings, we proceeded to determine whether the stroma (a) hMSCs were treated for 1 week with regular medium, recombinant human IL-1β peptide (25 pg/ml) or CM from PC3-ML cells with and without anakinra (10 μg/ml). Cells were then stained for α-smooth muscle actin (red) and DAPI (4,6-diamidino-2-phenylindole; blue), revealing linear stress fibers in response to both IL-1β and PC3-ML CM, which were abrogated by the inclusion of anakinra. (b) hMSCs treated as above were lysed and subjected to western blotting for actin and the CAF marker S100A4, which was upregulated in response to IL-1β and PC3-ML CM, an effect fully abolished in the presence of anakinra. (c) SCID mice WT and null (KO) for IL-1R were inoculated with fluorescently labeled PC3-ML human prostate cancer cells and killed after 3 weeks; LCM was used to harvest bone stromal regions adjacent to tumors (red), distant from tumors (yellow) and from tumor-free bones (green). (d) Upon qRT-PCR analysis of these samples, S100A4 was found to be specifically upregulated exclusively in the tumorassociated stroma of WT animals, indicating a local effect dependent on IL-1β signaling. Similarly, the IL-1β downstream target COX-2 was upregulated only in WT tumor-associated stroma. Samples from three animals of each genotype were analyzed. (Data are expressed as mean ± s.e.; ***P = 0.0002; *P = 0.002 by one-way analysis of variance with Tukey's post-test).
surrounding skeletal metastases in our animal model responded to tumor-secreted IL-1β in a similar manner. Bone stroma immediately adjacent to and some distance away from tumors generated by PC3-ML cells was harvested by laser capture microdissection (LCM) from IL-1R WT mice ( Figure 2c , left); in the same animals, stroma from bones that did not harbor any tumors was also collected (Figure 2c , middle), as were analogous samples from IL-1R knockout mice (Figure 2c , right). These tissues were tested for S100A4 and COX-2 expression, as both molecules are known to be induced in stromal cells by exposure to IL-1β, 5, 14 and S100A4 expression would indicate the development of CAFs in the metastatic niche. 15 We detected a strong induction of both markers in the bone stroma of WT animals immediately adjacent to the skeletal tumors relative to the normal tissue. This effect appeared spatially delimited: stroma located some distance from tumors was only minimally affected, likely owing to the concentration gradient of IL-1β secreted by the cancer cells. Further, in IL-1R knockout animals the expression of stromal S100A4 and COX-2 was totally unaffected by the presence of tumors, confirming the causal role of IL-1 signaling in this process ( Figure 2d ).
IL-1β affects the expression of tumor-related genes in the bone stroma The growth-permissive niche generated by IL-1β likely involves alterations in local concentrations of molecular mediators produced by cells either naturally inhabiting the bone stroma or migrating to the tumor-colonized tissue microenvironment. With the intent to identify specific genes altered by IL-1β signaling in tumor-associated bone stromal cells, we interrogated the same LCM mouse tissue specimens analyzed above for S100A4 and COX-2 expression by using Nanostring technology and an nCounter panel of 750 genes with established relevance in adaptive, humoral and innate immune response as well as inflammation. We detected 30 genes for which expression was significantly altered twofolds or more by the presence of PCa cells as compared with bone stroma either free of tumors or harvested from IL-1R KO animals ( Table 1) .
Correlation between IL-1β expression and AR status in human skeletal metastases In order to translate our results using animal models to human metastatic disease, we investigated IL-1β expression in archival bone biopsies obtained from 10 patients in two different clinical cohorts and with documented post-androgen-deprivation therapy castration-resistant PCa. In previous studies, we had observed a negative correlation between prostate-specific antigen immunostaining (as a measure of AR transcriptional activity) and IL-1β expression in bone metastases from a different cohort of patients. 5 In this new group of patients, we found that the AR − PCa cells showed high IL-1β expression, while the AR+ cells tested completely negative for this cytokine. Interestingly, these specimens revealed remarkable variability of AR staining within individual lesions (Figure 3a , arrows), while in some areas the AR could be detected in only a minority of cancer cells (Figure 3a , dotted line). Overall, 430% of cancer cells identified by morphological and histopathological criteria in these 10 patients did not stain for AR (Figure 3b ). Furthermore, dual immunofluorescence staining with an AR and a pan-cytokeratin antibody 16 indicated that the cancer cells identified in these metastatic lesions, both with and without AR expression, were of epithelial origin, as can be seen at both primary ( Figure 3c ) and bone metastatic sites (Figure 3d ). To provide molecular validation of these findings, we employed LCM to harvest tumor and stromal tissues (Supplementary Figure S1 ) from two of the same bone metastasis specimens examined by immunohistochemical (IHC) staining (patients 2 and 4) and analyzed them by quantitative reverse transcriptase-PCR (qRT-PCR). The prostatic origin of both AR+ and AR − tumor cells was conclusively established by the equivalent levels of mRNA for prostein (also known as SLC45A3 or P501S), which is highly restricted to both normal and malignant prostate cells and is routinely used for the diagnosis of metastatic lesions [17] [18] [19] ( Figure 3e ). The AR status indicated by IHC staining was confirmed at the transcriptional level ( Figure 3f ). Notably, AR − cancer cells did not express molecular neuroendocrine (NE) markers such as synaptophysin or chromogranin A 20, 21 (Supplementary Table S1 ), in contrast to a lung metastasis from another patient that stained negative for AR expression but expressed NE markers, as is frequently observed in visceral lesions typical of advanced PCa. (Supplementary Figure S2 and  Supplementary Table S1 ).
In comparison to AR − cancer cells, bone stroma expressed significantly lower levels of IL-1β transcript (Figure 3g ). This indicates that PCa cells have a dominant role in dictating the local levels of IL-1β during colonization of the skeleton, in contrast to what has been previously proposed by others using subdermal implant of bioengineered scaffolds. 22 The bone stroma conditioned by metastatic cells supports also the colonization of cells with indolent metastatic behavior We surmised that PC3-ML cells could also be supportive of indolent cancer cells that are incapable of independently generating the molecular crosstalk necessary to support survival and therefore fail to colonize the bone. To test this hypothesis and in light of the pro-metastatic role of IL-1β revealed by our study thus far, we first assessed the expression of this cytokine in additional human PCa cells either lacking (DU-145) or expressing (LNCaP, VCaP and 22Rv1) the AR. We found all cell types to be negative for IL-1β ( Figure 4a ) and unable to metastasize in our animal model, despite successfully arriving to the skeleton via the arterial circulation and homing as disseminated tumor cells. This is consistent with our previous work with DU-145 cells, 8, 5 with the lack of published studies with LNCaP and VCaP cells in preclinical models of bone metastasis and only two existing reports for 22Rv1 cells, 23, 24 the results of which could not be reproduced in our hands. We then generated PC3-ML cells stably expressing both the fluorescent protein mCherry and RedLuc to be paired with the various nonmetastatic cell lines, which were engineered to express green fluorescent protein (GFP) and Luc2. Co-inoculation experiments were then conducted to ascertain whether metastatic PC3-ML cells could support colonization of the skeleton by independently non-metastatic cells in mice (Figure 4b ). We found that this was indeed the case, as mixed tumors could be detected by bioluminescent imaging and multispectral fluorescence microscopy for all cell combinations (Figures 4c  and d) . At 4 weeks, animals in each study were found to harbor skeletal tumors comprised solely of PC3-ML cells as well as mixed tumors located in the upper limbs, lower limbs and spine.
Cooperation between cancer cells starts early after seeding the bone marrow Next we sought to determine whether the cooperation among cancer cells revealed by the experiments described above is an early event or one that takes time to be established. To dissect the earliest stages of metastasis, we examined the bones of animals killed 24 h after intracardiac co-inoculation of PC3-ML cells and a non-metastatic cell line. These animals revealed that the presence of PC3-ML cells led to a significant increase in the number of non-metastatic 22Rv1 and VCaP cells found in the skeleton, compared to unaccompanied inoculation of these cells (Figures 5a and b) . These findings denote a pro-metastatic role for PC3-ML cells that begins very rapidly after the initial lodging of cancer cells in the skeleton and leads to critical changes in the bone microenvironment during the first 24 h of seeding. Although these data might hint to a role for IL-1β in the bone metastatic niche, we had yet to understand the trajectory of the crucial IL-1 signaling. To this end, we assayed the various PCa cell lines used in this study for expression of the IL-1R in order to determine their potential receptivity to paracrine IL-1β signaling and found the receptor present in each (Figure 5c ). However, exposure to IL-1β peptide in vitro revealed a varying profile of signal transduction among two AR+ PCa cell lines that benefited equally from PC3-ML cells when colonizing the bone, suggesting that paracrine stimulation of IL-1R is unlikely to be primarily responsible for the metastatic cell cooperation we observed (Figure 5d ). On the other hand, hMSCs, which are an abundant component of the bone stroma, when similarly exposed to IL-1β 
exhibited a rapid and sustained signaling response, indicating definite susceptibility to this cytokine (Figure 5e ). Interestingly, we showed the cooperative arrival effect appear to be specific to the bone microenvironment, as no difference in seeding was observed in the lungs of the animals described above (Figures 5f  and g ).
Exogenous expression of IL-1β is sufficient to induce a metastatic phenotype that cooperates with indolent cancer cells Here we sought to strengthen the findings described above by testing the role of IL-1β in supporting cells lacking this cytokine and unable to independently metastasize. To this end, we generated non-metastatic DU-145 cell line engineered to stably express high levels of IL-1β (Figure 6a ), which we have previously shown to impart them with de novo metastatic ability. 5 Notably, these cells would-at least in part-mimic the AR − / IL-1β-expressing phenotype of PC3-ML cells and be consistent with the inverse correlation between AR and IL-1β that we had observed in skeletal metastases from PCa patients. These newly generated DU-145 cells were labeled with mCherry/Red Luc and co-injected with GFP/Luc2-labeled VCaP cells, and the mice were killed after either 24 h or 3 weeks later. Upon examination of their femora and IL-1β in skeletal metastasis from prostate cancer K Shahriari et al tibiae, which we routinely inspect to assess cancer cell seeding, 25 we found a significant increase in arrival of VCaP cells (Figure 6b ) and generation of mixed tumors (Figure 6c ) relative to their solitary inoculation.
DISCUSSION
Given our previous findings regarding the importance of IL-1β expression to the bone metastatic behavior of human PCa cells, 5 we sought to determine whether this cytokine exerts a functional role in promoting metastasis through experimental interference with its signaling. To strictly address the clinical scenario of advanced PCa in a preclinical setting, we focused on late stages of the metastatic process: bone colonization and progression into macroscopic skeletal lesions. Our studies provide first and convincing evidence that interfering with IL-1R activation using a Food and Drug Administration-approved drug such as anakinra 26 impairs tumor growth at the skeletal level in a clinically relevant animal model of metastatic PCa. Significantly, experiments with transgenic knockout mice showed that the aggressive bone metastatic behavior of PC3-ML cells was severely undermined by the absence of IL-1R expression by the tissue hosting the cancer cells. This hints to an essential role for IL-1β secreted by PCa cells in recruiting cellular components of the bone microenvironment to establish a tumor-receptive metastatic niche. Additional experiments pointed to hMSC as a cell type likely involved in this tumor-stroma crosstalk, as these cells converted into CAFs in vitro when exposed to CM from PC3-ML cells and we detected elevated markers of this conversion such as S100A4 and COX-2 in the bone stroma closely associated with tumors. The fact that both markers have been also mechanistically implicated in the tumor-promoting role of CAFs 14, 27 provides additional support to the idea of a bone stroma reciprocating to PCa-mediated IL-1β signaling by promoting metastatic colonization. Furthermore, our gene profiling studies identify alterations in mediators of tumor growth and progression affecting the bone stroma within the metastatic niche. In addition to confirming the upregulation of COX-2 previously detected by qRT-PCR, we found that the upregulation of Integrins α1, β2 and β4, Osteopontin, tumor necrosis factor (TNF) 13 (TNF13 or BAFF) and TNF receptor 17 both corroborates earlier studies by others [28] [29] [30] and delineates a profile of pro-tumorigenic genes regulated by IL-1β secreted by metastasis-initiating cells. Equally compelling is the sevenfold downregulation of IL-24, a cytokine with a pleiotropic tumorsuppressing role that involves decreasing stemness of human PCa cells, 31 which supports the need for lessening its expression during tumor colonization of the metastatic niche. On the same line, downregulation of two initiating components of the Complement cascade (C1r and C1s) and of Manna-binding lectin serine peptidase 2 32 hints to an impairment of the innate immune-response, which has been proposed to control tumor growth via several types of immune cells, including natural killer cells. 33, 34 As natural killer cells are normally present in SCID mice, which were used in our study, these results delineate a conceivable scenario in which tumor-derived IL-1β mitigates the killing of cancer cells by innate immune response in the bone microenvironment.
By examining human specimens from metastatic patients, we revealed an inverse correlation between IL-1β and AR expression in PCa cells. Molecular analyses conclusively show that approximately one-third of cancer cells in skeletal lesions do not express AR and, in contrast to AR+ cancer cells, are highly positive to IL-1β. Remarkably, these AR − phenotypes do not express NE markers, 35 differing from visceral metastases typical of the advanced disease 36, 37 and most likely could not be traced either to a The relative fractions of mixed tumors for each non-metastatic cell type were as follows: 59% for LNCaP (9 mice), 78% VCaP (9 mice), 59% 22Rv1 (13 mice), and 93% for DU-145 (4 mice).
IL-1β in skeletal metastasis from prostate cancer K Shahriari et al primary small-cell carcinoma or to AR+ PCa cells transitioning into an NE phenotype. 38, 35 Even in light of the recognized dynamic regulation of both AR 39, 40 and IL-1β expression, 41 our study reveals a bone metastatic environment in which PCa cells may display either a stable or fluctuating AR − /IL-1β+ phenotypes but are-at any given time-numerically relevant and likely capable of coercing the stroma into a niche favorable to tumor growth by secreting IL-1β.
The AR − /IL-1β+ phenotypes detected in patients are mimicked by PC3-ML cells, which were found capable of supporting skeletal colonization and growth of both AR − (DU-145) and AR+ (LNCaP, VCaP and 22Rv1) PCa cells that lack IL-1β and fail to metastasize independently. The heterogeneous tumors generated in our animal models are particularly compelling as they reproduce the scenario observed in patients and overall reflect the widely reported genetic, hormonal and likely functional heterogeneity of cancer cells in human metastases. 42, 43 A highly speculative but yet intriguing concept is that DU-145 cells could exemplify an AR − PCa phenotype not expressing IL-1β and thus lacking bone tropism, as shown by their derivation from a human brain metastasis. 44 However, the possibility of rare subpopulations of AR − PCa cells lacking IL-1β and coexisting with AR − /IL-1β+ cancer cells in PCa bone metastases is also plausible.
Nonetheless, the exogenous expression of IL-1β in DU-145 cells was sufficient to confer bone metastatic behavior 5 as well as the ability to support the initial colonization of non-metastatic PCa cells after arrival to the skeleton.
In conclusion, our study provides preclinical evidence that the conditioning of the bone stroma by tumor-derived IL-1β spawns a niche permissive to the growth of PCa cells, outlines IL-1β as Figure 5 . Cooperation between metastatic and non-metastatic prostate cancer cells is an early event. Co-inoculation with PC3-ML cells dramatically increased the number of 22Rv1 or VCaP that lodged to the bone (a and b) when compared with either of these cell types inoculated alone. All AR − and AR+ prostate cancer cells examined express IL-1R (c). However, 22Rv1 and VCaP cells showed diverging signaling in response to exogenous treatment with IL-1β (d), whereas hMSC responded to the cytokine with a strong activation of the nuclear factor-κB pathway (e). In the lungs, the number of 22Rv1 cells detected 24 h postinoculation was independent of co-inoculation of PC3-ML cells (f and g). Results are shown as mean ± s.e; three animals for each group. **P = 0.01, and ***P = 0.006 by Student's t-test. Magnification: × 200.
IL-1β in skeletal metastasis from prostate cancer K Shahriari et al orchestrating heterotypic cell-cell communications and reveals a complex skeletal metastatic environment, in line with similar cellular dynamics observed in primary tumorigenesis. 45 Collectively, these results hint to a conceivable metastasis-promoting role for AR − /IL-1β+ PCa cells, describe and characterize a previously unknown functional heterogeneity in metastatic PCa and provide a strong incentive for clinical testing of pharmacological agents targeting both IL-1β signaling and stromal reciprocation, either as a standalone approach or in combination with the current standard of care.
MATERIALS AND METHODS
Cell lines and culture DU-145, 22Rv1, LNCaP and VCaP human PCa cell lines were purchased from ATCC (Manassas, VA, USA); the PC3-ML cell line was derived from the parental PC-3 cell line as previously described. 7 All cell lines were cultured at 37°C and 5% CO 2 , authenticated by short tandem repeat profiling by IDEXX Radil and/or DDC Medical and discarded 10 passages after thawing. We used Dulbecco's Modified Eagle Medium (DU-145, VCaP and PC3-ML) or RPMI-1460 (22Rv1 and LNCaP) containing 10% fetal bovine serum and 0.1% gentamicin. Bone marrow-derived human MSCs (Lonza, Walkersville, MD, USA) were used between passage 5 and 8 and cultured in α-Minimum Essential Medium supplemented with 10% fetal bovine serum, 1 ng/ml bFGF (R&D, Minneapolis, MN, USA) and 0.1% gentamicin. CM experiments were performed as previously described. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting
Western blotting analysis was performed as previously described. Animal studies and statistics Male C.B17-SC mice (Taconic, Hudson, NY, USA) at 6-8 weeks of age were anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg) prior being inoculated with cancer cells via the left cardiac ventricle. 47 Animals that upon being imaged 1 week after inoculation showed a diffuse bioluminescence signal in the chest area were deemed misinjected and therefore excluded from the study. For anakinra experiments, animals received subcutaneous injections of vehicle (phosphate-buffered saline) or anakinra (Swedish Orphan Biovitrum, Stockholm, Sweden) at the indicated doses. All experiments were performed in accordance with NIH guidelines for the humane use of animals. The Drexel University College of Medicine Institutional Animal Care and Use Committee approved all protocols involving the use of animals.
For this study, we used descriptive statistics. A prespecified effect size was not selected prior to conducting the experiments. After intracardiac injection, the experimenter distributed each animal in unlabeled cages. Each cage was randomly assigned to different treatment groups by a second experimenter. In the assessment of the outcome for in vivo imaging of longitudinal studies, the experimenter was not blinded but was assisted by the IVIS Living Image Software (PerkinElmer) in calculating the site and Figure 6 . Exogenous expression of IL-1β confers a pro-metastatic supportive role to PCa cells. DU-145 cells engineered to overexpress IL-1β (a) and co-inoculated with VCaP cells replicated the supportive effect provided by PC3-ML cells ((b) and generated mixed tumors detected by in vivo bioluminescence imaging (c)). Results are shown as mean ± s.e; three animals for each group. *P = 0.03 by Student's t-test. extent of photon emission as indications of tumor localization and growth, respectively. For the detection and enumeration of single tumor cells, the experimenter was not blinded but was assisted by the Nuance FX multiplex imaging software (PerkinElmer). A fluorescence image was acquired for each tissue section analyzed; the identification and enumeration of single cells was obtained by three different experimenters, including the Principal Investigator, and occasional discrepancies was reconciled prior to compiling the final data. One-way analysis of variance was used to compare multiple experimental groups. Student's t-test with Welch's correction (Prism 5.0, GraphPad Software, San Diego, CA, USA) was used to compare two experimental groups assuming no equal variance.
Generation of IL-1R SCID mice IL-1R SCID mice were generated by crossing CB17-SC RF mice with transgenic animals knockout for IL-1R1 (OMIM 147810, from Dr Nancy McNamara, UCSF). These animals were then genotyped for the Prkdc scid mutation by PCR using the forward primer 5′-GGAAAAGAATTGGTATCCAC -3′ and reverse 5′-AGTTATAACAGCTGGGTTGGC-3′; the product was digested with AluI resulting in fragments of 68 and 11 bp (WT) and 38, 28 and 11 bp (SCID). IL-1R status was determined by multiplex PCR using the following primers: IL-1R WT Fwd-5′-CCACATATTCTCCATCACTC TGCTGGTA-3′, IL-1R WT Rev-5′-TTTCGAATCTCAGTTGTCAAGTGTGTCCC-3′, IL-1R KO Fwd-5′-CTGAATGAACTGCAG GACGA-3′, and IL-1R KO Rev-5′-ATACTTTCTCGGCAGGAGCA-3′, and resulting in amplification of fragments of 350 base pairs (WT allele) and 172 base pairs (knockout) (Supplementary Figure S3) . Once animals homozygous for Prkdc scid and heterozygous for IL-1R were obtained, the colony was maintained through intercross of IL-1R heterozygotes, with 6-8-week-old male WT and knockout littermates used for the experiments.
In vivo bioluminescence imaging
Prior to each weekly imaging session, animals were injected intraperitoneally with 150 mg/kg D-Luciferin (PerkinElmer) and anesthetized using 3% isoflurane and transferred to the chamber of an IVIS Lumina XR (PerkinElmer), where they received 2% isoflurane throughout image acquisition. Analysis was performed using the Living Image software, v4.3 (PerkinElmer).
Processing of animal tissues, fluorescence microscopy and morphometric analysis of animal metastases Bones and soft tissue organs were harvested and processed, and fluorescent images of disseminated tumor cells and tumor foci obtained as previously described. 5, 25 Tumor area measurements were conducted using the Nuance Software (v. 2.4, PerkinElmer) and calibration with a TS-M2 stage micrometer (Oplenic Optronics, Jiangsu, China). Statistical analysis between groups used unpaired, two-tailed Student's t-test or one-way analysis of variance test.
IHC and analysis of human bone metastases
De-identified FFPE biopsy specimens of bone metastatic lesions from two different cohorts of advanced PCa patients were obtained from the archives of the Departments of Pathology at Drexel University College of Medicine (5 patients) and at Thomas Jefferson University (5 patients) and stained using the aforementioned antibody against the N-20 region of the human Androgen Receptor or against Prostein (Clone 10E3). These biopsy specimens were used to determine AR expression in cancer cells across 57 distinct regions of interest. Two board-certified pathologists (FUG and YG) selected the tumor areas to be inspected for AR expression by examining paired serial sections stained with hematoxylin/eosin. Assessment of AR staining intensity was performed using the Aperio system and ImageScope software (Leica Microsystems, Buffalo Grove, IL, USA).
Laser capture microdissection
For LCM, mouse tissues were prepared and frozen in OCT compound and cut to 40-μm sections. Tissue slides were washed with ice-cold RNase-free water for 2 min and then immediately dehydrated using an ethanol gradient in order to maintain RNA integrity.
For four human specimens, human FFPE sections subsequent to those used for IHC were deparaffinized in ice-cold xylene substitute for 15 min and dehydrated in ethanol for 30 s. LCM was performed using a PALM MicroBeam system (Zeiss). Microdissected tissues were catapulted into Zeiss AdhesiveCap 200 tubes and stored at − 80°C until RNA extraction.
qRT-PCR
Microdissected tissue samples were slowly thawed at room temperature, followed by RNA extraction using the RNeasy FFPE Kit (Qiagen, Hilden, Germany). Human RNA samples were amplified using the Ovation Pico WTA system V2 (NuGEN, San Carlos, CA, USA). Extracted mouse RNA samples and amplified human cDNA samples were stored at − 80°C until qRT-PCR was performed using an Applied Biosystems 7900HT Fast Real-Time PCR System. Gene-specific primer probe sets were purchased from Applied Biosystems/Life Technologies (ThermoFisher Scientific; Supplementary Table S2 ).
Nanostring Profiling
We used 100 ng of total RNA (20 ng/μl) on the nCounter Pan Cancer immune profiling for mouse (Nanostring, Seattle, WA, USA), which includes 750 genes with established relevance in immune response and 40 housekeeping genes used for normalization and selected with a geNorm algorithm. The nSolver (v.2.5) user interface (Nanostring) was used to operate the nCounter Advanced analysis module, which employs the R statistical software.
